Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04659629




Registration number
NCT04659629
Ethics application status
Date submitted
9/11/2020
Date registered
9/12/2020

Titles & IDs
Public title
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Scientific title
A First-in-Human Phase 1 Study of NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Secondary ID [1] 0 0
NL201-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Solid Tumor 0 0
Advanced Solid Tumor 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - NL-201
Treatment: Drugs - Pembrolizumab Injection [Keytruda]

Experimental: Part 1: NL-201 Monotherapy Dose Escalation - NL-201 given as monotherapy by intravenous administration testing ascending doses and two different schedules.

Experimental: Part 2: NL201 Monotherapy Expansion Cohorts - NL-201 given as monotherapy by intravenous administration in indication specific cohorts at a dose and schedule determined in Part 1.

Experimental: Part 3: NL-201 in Combination with Pembrolizumab Dose Escalation - NL-201, in combination with a set Pembrolizumab dose, testing ascending doses and two different schedules

Experimental: Part 4: NL-201 in Combination with Pembrolizumab Expansion Cohorts - NL-201 in combination with Pembrolizumab in indication specific cohorts at a dose and schedule determined in Part 3


Treatment: Drugs: NL-201
NL-201 is a de novo protein therapeutic.

Treatment: Drugs: Pembrolizumab Injection [Keytruda]
A programmed death receptor-1 (PD-1)-blocking antibody
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Recommended phase 2 dose (RP2D) for NL-201 (Parts 1 and 2)
Timepoint [1] 0 0
Up to Day 33
Primary outcome [2] 0 0
Recommended dose schedule for NL-201 (Parts 1 and 2)
Timepoint [2] 0 0
Up to Day 33
Primary outcome [3] 0 0
Recommended phase 2 dose (RP2D) for NL-201 in combination with Pembrolizumab (Parts 3 and 4)
Timepoint [3] 0 0
Up to Day 33
Primary outcome [4] 0 0
Recommended dose schedule for NL-201 in combination with Pembrolizumab (Parts 3 and 4)
Timepoint [4] 0 0
Up to Day 33
Primary outcome [5] 0 0
Incidence of treatment-emergent adverse events
Timepoint [5] 0 0
Up to Day 33
Primary outcome [6] 0 0
Severity of treatment-emergent adverse events
Timepoint [6] 0 0
Up to Day 33
Secondary outcome [1] 0 0
Best Objective Response according to RECIST version 1.1
Timepoint [1] 0 0
Up to 36 months
Secondary outcome [2] 0 0
Objective Response Rate (ORR) according to RECIST version 1.1
Timepoint [2] 0 0
Up to 36 months
Secondary outcome [3] 0 0
Progression-Free Survival (PFS) according to RECIST version 1.1
Timepoint [3] 0 0
Up to 36 months
Secondary outcome [4] 0 0
Duration of Response (DOR) according to RECIST version 1.1
Timepoint [4] 0 0
Upto 36 months
Secondary outcome [5] 0 0
Pharmacokinetic (PK) profile of NL-201 by half-life (t1/2)
Timepoint [5] 0 0
Up to 24 Months
Secondary outcome [6] 0 0
Pharmacokinetic (PK) profile of NL-201 by area under the plasma concentration time curve (AUC)
Timepoint [6] 0 0
Up to 24 months
Secondary outcome [7] 0 0
Pharmacokinetic (PK) profile of NL-201 by maximum observed plasma concentration (Cmax)
Timepoint [7] 0 0
Up to 24 months
Secondary outcome [8] 0 0
Pharmacokinetic (PK) profile of NL-201 by volume of distribution (Vd)
Timepoint [8] 0 0
Up to 24 Months
Secondary outcome [9] 0 0
Terminal-Phase Elimination Rate Constant (ß) of NL-201
Timepoint [9] 0 0
Up to 24 months
Secondary outcome [10] 0 0
Immunogenicity of NL-201
Timepoint [10] 0 0
Up to 24 months

Eligibility
Key inclusion criteria
* Patients with measurable disease
* Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* At least 6 weeks from any prior nitrosurea or mitomycin C therapy; at least 4 weeks from any other prior chemotherapy or checkpoint inhibitor; at least 2 weeks from any kinase inhibitor
* Part 1 Only: Patients with relapsed or refractory advanced solid tumor, other than prostate cancer, who have progressed, not tolerated or are ineligible for all approved lines of therapy
* Part 2 Only: Patients with kidney and skin cancer who have failed at least 1 line of systemic therapy
* Part 3 Only: Patients with solid tumors who have received = 1 prior line of therapy for advanced or metastatic disease
* Part 4 Only: Patients with diagnosed target disease OR previously received pembrolizumab
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prostate Cancer
* Any serious medical condition or laboratory abnormality or psychiatric condition or any other significant or unstable concurrent medical illness (in the opinion of the Investigator) would preclude protocol adherence or would make the safety of the study drug difficult to assess
* Known or suspected SARS-CoV-2 infection, unless patient tests negative for SARS-CoV-2 within the Screening period
* History of solid organ transplant or bone marrow transplant
* Prior chimeric antigen receptor T-cell (CAR-T) or allogeneic cellular therapy
* Prior IL-2-based cancer therapy
* Ongoing systemic immunosuppressive therapy
* Concurrent therapy with any other investigational agent, vaccine, or device.
* Part 3 and 4 Only: History of (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Part 3 and 4 Only: Known additional cancer that is progressing or has required active treatment within the past 2 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (eg, breast carcinoma, cervical cancer in situ) that have undergone curative resection are eligible.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/04/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/08/2024
Sample size
Target
Accrual to date
Final
59
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Melanoma Institute Australia - Sydney
Recruitment hospital [2] 0 0
St Vincents Hospital - Sydney
Recruitment hospital [3] 0 0
Olivia Newton-John Cancer Wellness & Research Centre - Heidelberg
Recruitment postcode(s) [1] 0 0
2065 - Sydney
Recruitment postcode(s) [2] 0 0
- Sydney
Recruitment postcode(s) [3] 0 0
- Heidelberg
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
New York
Country [2] 0 0
United States of America
State/province [2] 0 0
Oregon
Country [3] 0 0
United States of America
State/province [3] 0 0
Texas
Country [4] 0 0
United States of America
State/province [4] 0 0
Washington
Country [5] 0 0
Canada
State/province [5] 0 0
Ontario

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Neurogene Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Merck Sharp & Dohme LLC
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Albiruni A Razak
Address 0 0
UHN - Princess Margaret Cancer Center
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?




Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT04659629